| Similar Articles |
|---|
 |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises.   |
Pharmaceutical Executive
October 1, 2011
Daniel Vasella |
Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D. |
BusinessWeek
January 29, 2007
Kerry Capell |
GlaxoSmithKline: Getting AIDS Drugs To More Sick People GlaxoSmithKline sells 90% of its vaccines, in volume terms, at not-for-profit prices to customers in the developing world. |
Pharmaceutical Executive
April 1, 2011 |
Restoring Public Trust in Pharma Putting the focus on four steps to cement a new compliance culture. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
HBS Working Knowledge
February 28, 2005
Cynthia Churchwell |
Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution. |
Chemistry World
June 23, 2010
Sarah Houlton |
A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines. |
| Knowledge@Wharton |
Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy." |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
BusinessWeek
April 26, 2004
Kerry Capell |
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money. |
Pharmaceutical Executive
August 1, 2012
Carol Ann Williams |
Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine. |
BusinessWeek
July 25, 2005
Catherine Arnst |
O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge. |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
Pharmaceutical Executive
June 1, 2005
Seth Berkley |
Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer. |
Pharmaceutical Executive
December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Salon.com
June 1, 2001
Daryl Lindsey |
The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical? |
Pharmaceutical Executive
May 1, 2012 |
Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory. |
Pharmaceutical Executive
June 1, 2005
Peter J. Pitts |
Opinion: Uncle Sam, MD Is having the government pursue a patent the best way of placing important discoveries in the public domain? It depends. Is putting the government in control of drug development in the best interests of public health? No. |
Pharmaceutical Executive
July 1, 2011 |
Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy. |
The Motley Fool
January 21, 2010
Brian Orelli |
The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments. |
Pharmaceutical Executive
May 1, 2011
Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance. |
BusinessWeek
October 4, 2004 |
"It's a Perfect Storm" for Drugmakers Glaxo CEO Jean-Pierre Garnier answers questions about the biotech industry's hardships and how his company is improving its search for new drugs |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Popular Mechanics
August 6, 2009 |
Inventor Dean Kamen Says Healthcare Debate "Backward Looking" In the course of a wide-ranging interview, Kamen offers a strongly contrarian take on the current healthcare debate. |
Pharmaceutical Executive
September 1, 2008
Sarah Houlton |
Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive
September 1, 2006
Kieran Hartsough |
Benchmarking AIDS Pharma is taking on the global AIDS crisis. But who has crafted the best approach? The Interfaith Center on Corporate Responsibility defines best practices and matches major companies head-to-head. Grades are posted inside. |
Chemistry World
October 9, 2013
Phillip Broadwith |
GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months. |
Pharmaceutical Executive
November 1, 2011
William Looney |
R&D Costs: It's Industry's Problem If high prices that lower access are attributable to a flawed R&D model, can the pharmaceutical industry embrace delivering better results at lower costs. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
An 'A' for Advancing Expectations As head of both the Food and Drug Administration and the Centers for Medicare and Medicaid Services, Mark McClellan has been at the center of public policy affecting the pharmaceutical industry over the last decade. |
Pharmaceutical Executive
August 1, 2014 |
EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire? Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause. |
Fast Company
November 2002
Chuck Salter |
Richard Klausner Spends to Save Lives At the wealthiest foundation on the planet, a brilliant scientist is giving away Bill Gates's money in pursuit of a lofty goal: solving the world's most pressing health problems. |
Pharmaceutical Executive
June 1, 2014 |
Hopes High as EU Heads Into Leadership Change The principal drug industry associations in Europe launched a call in mid-May for "an integrated European industrial policy for the pharmaceuticals sector." |
Pharmaceutical Executive
September 1, 2005
Wolfgang Klietmann |
Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact. |
Scientific American
July 2006
JR Minkel |
Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive. |
Pharmaceutical Executive
July 3, 2007 |
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. |
Pharmaceutical Executive
January 1, 2009
Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
Pharmaceutical Executive
February 1, 2007
Joanna Breitstein |
Net Effect Ripley Ballou may finally win approval for a vaccine he started testing as an army physician more than 25 years ago - an advance that could mark the beginning of a whole new phase in the battle against one of the world's great killers: malaria. |
BusinessWeek
November 29, 2004
Kerry Capell |
"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome. |
Pharmaceutical Executive
August 1, 2013
Joseph Saba |
New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa. |
Pharmaceutical Executive
October 1, 2014
William Looney |
IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today. |
Chemistry World
July 29, 2015
Maria Burke |
Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear. |
Pharmaceutical Executive
September 1, 2012
Roy F. Waldron |
Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? |
Pharmaceutical Executive
October 1, 2011 |
Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
Pharmaceutical Executive
January 1, 2007
Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
Smithsonian
November 2005 |
35 Who Made a Difference: Bill Gates The king of software takes on his biggest challenge yet: his foundation is reshaping the landscape of deadly and debilitating diseases in the developing world. |
